Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Ashley Zimmerman, Keisha Heslop, Dustin Chapin, Taimur Sher, Vivek Roy, Ahsan Rasheed, Aneel Paulus, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 9331–9332.

https://doi.org/10.1182/blood-2022-165377

Published: 2022

Journal Articles

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Taimur Sher, Aneel Paulus, Dustin Chapin, Keisha Heslop, Asher Chanan-Khan, Vivek Roy

Blood (2022) 140 (Supplement 1): 4450–4451.

https://doi.org/10.1182/blood-2022-164656

Published: 2022

Journal Articles

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Sikander Ailawadhi, Ricardo D Parrondo, Aneel Paulus, Betsy Laplant, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Taimur Sher, Vivek Roy, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 9904–9905.

https://doi.org/10.1182/blood-2022-164667

Published: 2022

Journal Articles

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Sikander Ailawadhi, Ricardo D Parrondo, Gabriela Perez, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Ernesto Ayala, Patrick J O'Brien, Vivek Roy, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Stephanie Lanier, Carly Kasik, Schannon Bradley, Taimur Sher, Aneel Paulus, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 10165–10166.

https://doi.org/10.1182/blood-2022-165209

Published: 2022

Journal Articles

Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study

Sikander Ailawadhi, Jay R. Hydren, Leyla Bojanini, Nathan W. Sweeney, Felicia Seng, Mizba Baksh, Ahsan Rasheed, Mays Abdulazeez, Meghna Ailawadhi, Keren George, Ricardo D Parrondo, Vivek Roy, Victoria R. Alegria, Pooja Advani, Rami Manochakian, Jason S. Starr, Taimur Sher, Jennifer M. Ahlstrom, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 7941–7942.

https://doi.org/10.1182/blood-2022-167005

Published: 2022

Journal Articles

Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients

Meghna Ailawadhi, MD, Mays F Abdulazeez, MBBS, Leyla Bojanini Molina, MD, Victoria R. Alegria, Taimur Sher, MD, Vivek Roy, MD, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140390

Published: 2020

Journal Articles

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Ricardo Parrondo, MD, Muhamad Alhaj Moustafa, MD, Craig B. Reeder, MD, Taimur Sher, MD, Vivek Roy, MD, Rahma M Warsame, MD, Victoria R. Alegria, Wilson I Gonsalves, MD, Prashant Kapoor, MD, David Dingli, MD PhD, Suzanne R. Hayman, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139559

Published: 2020

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Mays F Abdulazeez, MBBS, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rahma M Warsame, MD, Jeremy Larsen, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Prashant Kapoor, MD, Rafael Fonseca, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Suzanne R. Hayman, MD, Craig B. Reeder, MD, Arshi Agrawal, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139929

Published: 2020

Journal Articles

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

Sikander Ailawadhi, MD, Meghna Ailawadhi, MD, Srilekha Bodepudi, Mays F Abdulazeez, BMSC, Zan Tahir Shareef, Ashna Grover, Maria J Fernandez, Winston Tan, MD, Victoria R. Alegria, Taimur Sher, MD, Vivek Roy, MD, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 411.

https://doi.org/10.1182/blood-2019-125722

Published: 2019

Journal Articles

A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)

Vivek Kumar, MD, M.B.,B.S., Meghna Ailawadhi, MD, Mays F Abdulazeez, MBBS, Suman Biswas, MD, Sri Lekha Bodepudi, Leyla Bojanini, MD, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 4779.

https://doi.org/10.1182/blood-2019-125156

Published: 2019

Journal Articles

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis

Vivek Kumar, MD, M.B.,B.S., Mays F Abdulazeez, BMSC, Suman Biswas, MD, Sri Lekha Bodepudi, Vivek Roy, MD, Taimur Sher, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Salman Ahmed, MD, Prachi Jani, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 71.

https://doi.org/10.1182/blood-2019-124799

Published: 2019

Journal Articles

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Aneel Paulus, MD, Victoria R. Alegria, Betsy Laplant, MS, Muhamad Alhaj Moustafa, MD, Dustin Chapin, Keisha Jackson, Prachi Jani, MD, Salman Ahmed, MD, Brett Edwards, Alak Manna, PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 1912.

https://doi.org/10.1182/blood-2019-128233

Published: 2019

Journal Articles

Sociodemographic and Clinical Characteristics Associated with Patient's Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes

Vivek Kumar, MD, M.B.,B.S., Mays F Abdulazeez, MBBS, Srilekha Bodepudi, Suman Biswas, Vivek Roy, MD, Taimur Sher, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 3494.

https://doi.org/10.1182/blood-2019-125888

Published: 2019

Journal Articles

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Victoria R. Alegria, Salman Ahmed, MD, Betsy Laplant, MS, Alak Manna, PhD, Ricardo Parrondo, MD, Vivek Roy, MD, Taimur Sher, MD, Brett Edwards, Stephanie Lanier, Keisha Jackson, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2019) 134 (Supplement_1): 3137.

https://doi.org/10.1182/blood-2019-128610

Published: 2019

Journal Articles

Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care

Vivek Kumar, MD, M.B.,B.S., Taimur Sher, MD, Leyla Bojanini, MD, Prakash Vishnu, MD, Vivek Roy, MD, Rami Manochakian, MD, Sri Lekha Bodepudi, Zan Tahir Shareef, Salman Ahmed, MD, Prachi Jani, MD, Victoria R. Alegria, Meghna Ailawadhi, MD, Aneel Paulus, MD, Sonikpreet Aulakh, MD, Madiha Iqbal, MBBS, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2018) 132 (Supplement 1): 4764.

https://doi.org/10.1182/blood-2018-99-120127

Published: 2018

Journal Articles

Trends in the Utilization of Radiation Therapy (XRT) Among Patients with Non-Hodgkin's Lymphoma (NHL) in the United States (US)

Vivek Kumar, MD, M.B.,B.S., Taimur Sher, MD, Prakash Vishnu, MD, Vivek Roy, MD, Anne M Hazen, A.R.N.P.,M.S.N, Victoria R. Alegria, Meghna Ailawadhi, MD, Salman Ahmed, MD, Prachi Jani, MD, Zan Tahir Shareef, Sri Lekha Bodepudi, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2018) 132 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2018-99-119981

Published: 2018

Journal Articles

Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States

Sikander Ailawadhi, Sri Lekha Bodepudi, Zan Tahir Shareef, Fabiola Coromoto Cardozo, Salman Ahmed, MD, Prachi Jani, MD, Shishir David, Vivek Roy, MD, Aneel Paulus, MD, Victoria R. Alegria, Vivek Kumar, MD, M.B.,B.S., Meghna Ailawadhi, MD, Prakash Vishnu, MD, Sonikpreet Aulakh, MD, Rami Manochakian, MD, Asher A. Chanan-Khan, MD, Taimur Sher, MD

Blood (2018) 132 (Supplement 1): 4861.

https://doi.org/10.1182/blood-2018-99-117155

Published: 2018

Journal Articles

Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL)

Vivek Kumar, MD, M.B.,B.S., Sikander Ailawadhi, Leyla Bojanini, MD, Aditya Mehta, Anshika Singh, Taimur Sher, MD, Vivek Roy, MD, Prakash Vishnu, MD, Julian A Marin-Acevedo, Victoria R. Alegria, Aneel Paulus, MD, Sonikpreet Aulakh, MD, Madiha Iqbal, MBBS, Rami Manochakian, MD, Winston Tan, MD, Asher A. Chanan-Khan, MD, Meghna Ailawadhi, MD

Blood (2018) 132 (Supplement 1): 4869.

https://doi.org/10.1182/blood-2018-99-116361

Published: 2018

Journal Articles

Sociodemographic Profile and Outcomes of Patients with Non-Diffuse Large B-Cell Lymphoma (non-DLBCL) Treated at Minority-Predominant Facilities in the United States

Vivek Kumar, MD, M.B.,B.S., Taimur Sher, MD, Vivek Roy, MD, Prakash Vishnu, MD, Anne M Hazen, A.R.N.P.,M.S.N, Victoria R. Alegria, Meghna Ailawadhi, MD, Sri Lekha Bodepudi, Zan Tahir Shareef, Fabiola Coromoto Cardozo, Salman Ahmed, MD, Prachi Jani, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2018) 132 (Supplement 1): 4868.

https://doi.org/10.1182/blood-2018-99-119976

Published: 2018

Journal Articles

Utilization of Radiation Therapy in Multiple Myeloma: Trends and Changes in Practice

Sikander Ailawadhi, Ryan D. Frank, Zahara Meghji, Prachi Jani, MD, Raj Patel, MD, Mark A. Fiala, BS, Tanya S. Kakar, Sonikpreet Aulakh, MD, Ankita Aggarwal, David O. Hodge, MS, Taimur Sher, MD, Vivek Roy, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Prakash Vishnu, MD FACP, Aneel Paulus, MD, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 3395.

https://doi.org/10.1182/blood.V130.Suppl_1.3395.3395

Published: 2017

NARROW

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study

Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sociodemographic and Clinical Characteristics Associated with Patient's Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care

Trends in the Utilization of Radiation Therapy (XRT) Among Patients with Non-Hodgkin's Lymphoma (NHL) in the United States (US)

Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States

Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL)

Sociodemographic Profile and Outcomes of Patients with Non-Diffuse Large B-Cell Lymphoma (non-DLBCL) Treated at Minority-Predominant Facilities in the United States

Utilization of Radiation Therapy in Multiple Myeloma: Trends and Changes in Practice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only